Radiology accounts for 76% of all FDA-cleared AI/ML-enabled medical devices as of the end of 2025.
Key Details
- 1A longitudinal analysis covered 1,430 FDA-authorized AI/ML medical devices between 1995 and late 2025.
- 2Annual authorization of such devices jumped from 1.8 (1995-2014) to 264 per year (2023-2025), with 331 approvals in 2025 alone.
- 3Radiology devices represented 76.5% (1,094 of 1,430) of all authorized devices; cardiovascular and neurology followed.
- 4Most devices (96%) went through the streamlined 510(k) approval pathway; De Novo and PMA routes were rare.
- 5740 companies contributed devices, but only 13 made up 17.3% of authorizations, indicating market concentration.
- 6Several clinical specialties (e.g., pathology, OB/GYN, psychiatry) had very few or no authorized AI devices.
Why It Matters
This analysis underscores radiology's central role in AI medical device innovation and regulatory clearance, shaping the present and future landscape of imaging AI in medicine. The findings highlight both rapid progress and areas where broader adoption is needed, informing researchers, vendors, and policymakers.
Source
AuntMinnie
Related News
•Radiology Business
RadNet AI Tool Reduces Unnecessary Prostate Biopsies by 19%
RadNet's DeepHealth AI tool can help avoid nearly 1 in 5 prostate biopsies while maintaining high cancer detection sensitivity.
•Radiology Business
Multi-Vendor AI Adoption Delivers Efficiency Gains in Private Radiology
A large-scale European study shows that adopting multiple AI tools in private radiology practices leads to significant efficiency improvements.
•Radiology Business
GE HealthCare Appoints Chief AI Officer to Lead Imaging Innovation
GE HealthCare has hired Rodolphe Katra as its new global chief AI officer to drive its AI strategy in imaging.